Verified Clinical Trials (VCT) is proud to announce our participation at the upcoming American Diabetes Association (ADA) annual meeting. As clinical research in diabetes, obesity, and GLP-1 therapies continues to expand at a record pace, VCT remains committed to delivering innovative solutions that safeguard data integrity, improve participant safety, and optimize trial outcomes by preventing professional patients and duplicate subjects in clinical trials.
The Growing Challenge of Duplicate Subjects in Diabetes & Obesity Trials
The explosion of clinical trials in the GLP-1, obesity, and diabetes therapeutic space has created an unprecedented landscape where patients may attempt to enroll in multiple studies simultaneously. With numerous ongoing trials and limited access to these highly sought-after prescription medications outside of research, many subjects are motivated to pursue multiple enrollment opportunities. This has led to the emergence of “professional patients” and duplicate subjects who attempt to participate in multiple studies for financial gain, medication access, or both.
Studies have shown that the incidence of duplicate subjects in these trials typically ranges from several percent to as high as 10%, depending on the indication and geography. These violations often occur during the critical early stages of screening and enrollment, well before most detection tools or internal site processes can intervene.
Verified Clinical Trials: The Only Solution Capable of Prevention at Screening
Unlike retrospective data reviews or analytics that attempt to identify anomalies after enrollment or even after dosing, Verified Clinical Trials is unique in its ability to detect and prevent duplicate subjects and protocol violations at the time of screening. Our cross-sponsor, cross-therapeutic, global registry acts as a frontline defense before any study-related procedures or dosing takes place. This proactive approach not only protects subject safety but also prevents costly downstream issues such as invalid data, increased placebo responses, protocol deviations, and potential trial delays.
The Cost of Missed Violations
The cost of allowing duplicate subjects to slip through can be staggering. Once a subject is screened, randomized, and dosed, the financial burden includes drug shipment and administration, site monitoring, laboratory evaluations, imaging, data analysis, and possible adverse event management. Should a violation be detected later, sponsors often face costly protocol amendments, re-screening, and sometimes entire cohort replacements. VCT eliminates these risks upfront, saving sponsors significant time and money.
A Trusted Industry Partner
Today, many of the leading pharmaceutical companies developing GLP-1 and diabetes therapies have already integrated Verified Clinical Trials into their clinical trial operations. VCT serves as a neutral, independent third-party solution, working with sponsors, CROs, sites, and networks to strengthen data quality and ensure regulatory compliance.
We look forward to engaging with industry colleagues at the ADA meeting to discuss how Verified Clinical Trials can protect your studies and contribute to more reliable, efficient clinical development programs.
For more information about the ADA annual meeting, please visit: https://professional.diabetes.org/meetings
If you would like to schedule a meeting with Verified Clinical Trials during the ADA conference, please contact us directly or visit our website at: https://verifiedclinicaltrials.com.
